Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.06), $1.03 better than the analyst estimate of ($2.09). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $5.42 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Raised to $61 at TD Cowen
• First Internet Bancorp (INBK) Tops Q1 EPS by 5c
• RBC Capital Starts Ultragenyx Pharma (RARE) at Outperform 'Given Base Business Offers Downside Protection & OI Material Upside Potential'